CEPHEID  (CPHD) Trade Now »     Rate CPHD  -  Discuss CPHD  -  Add to Watch List        

On Thursday, Cepheid (CPHD) reported $42.1 million in quarterly revenues, a 55% jump from the $27.2 million reported in the same period last year. (Call Transcript)

Growth has been driven by hospitals' intent on countering the growing scourge of healthcare associated infections [HAI].

Filed under: Newsletters, Stocks to Buy

"I still love Cepheid (NASDAQ: CPHD)," says biotechnology sector expert Michael Shulman in his ChangeWave Biotech Investor.

The advisor explains, "Cepheid does genetic testing of the things that can make us sick or kill us. The company is at the forefront of the next generation of diagnostics testing, and has real products already on the market." Here is his review.

"Cepheid has had outrageous sales success in the past few quarters and, therefore, has excellent profits looming. However, the true value for the company is its long-term potential.

"I still love Cepheid (NASDAQ: CPHD)," says biotechnology sector expert Michael Shulman in his always-fascinating ChangeWave Biotech Investor.

The advisor explains, "Cepheid does genetic testing of the things that can make us sick or kill us. The company is at the forefront of the next generation of diagnostics testing, and has real products already on the market." Here is his review.

"Cepheid has had outrageous sales success in the past few quarters and, therefore, has excellent profits looming. However, the true value for the company is its long-term potential.